Navigation Links
Lumenis One Multi-Spot Nd:YAG Module

ProductsLumenis One Multi-Spot Nd:YAG Module
Company Lumenis Inc.
Item Lumenis One Multi-Spot Nd:YAG Module
Features 
  • Easy-to-navigate interface developed by user interface designers working hand-in-hand with experts in aesthetic medicine to be thorough, yet incredibly easy to operate.
  • Searchable database lets you instantly access, query, and download detailed patient treatment records.
  • Fastwith up to 1-Hz Nd:YAG treatments and multiple spot sizes: 2x4 mm, 6 mm and 9 mm.
  • Most compact Nd:YAG treatment head available.
  • Continuous contact cooling for patient comfort.
  • SapphireCool contact cooled sapphire Light Guides for patient comfort and enhanced durability.
  • Built-in calibration.
  • Ergonomic design: simple operation, lightweight head, and elongated light guide for greater visibility to treatment area.
Description Using proven 1064 nm technology for the treatment of deeper lesions, the Lumenis One Multi-Spot Nd:YAG module provides versatility allowing targeted treatment of leg veins, vascular lesions, facial wrinkles and more.
Info Lumenis Inc.
Customer Service: 877-lumenis
Web site: http://www.lumenis.com

Related medicine products :

1. Lumenis VersaPulse PowerSuite
2. Lumenis 950 Slit Lamp
3. Lumenis 1000 Integrated Slit Lamp
4. Smartepil II Long Pulse Nd:YAG Laser
5. KTP/Nd:YAG "XP" Surgical Laser System
6. Ceralas G5 Diode-Pumped Nd:YAG Laser
7. 800 Series KTP/Nd:YAG "XP" Surgical Laser System
8. Dodick Nd:YAG photolysis system
9. MYDON Long-Pulsed Nd:YAG Laser System
10. Selecta 1064 nm Nd:YAG Base Platform
11. CoolGlide Excel Nd:YAG Laser
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8The American Legion Calls for Revamping and Expansion of Veterans and Military Health Care 55198 1The American Legion Calls for Revamping and Expansion of Veterans and Military Health Care 55198 2New Study of House Health Reform Bill 3A California Faces Over 243 7 Billion in Medicare Funded Nursing Home Cuts Over Ten Years 55196 1New Study of House Health Reform Bill 3A California Faces Over 243 7 Billion in Medicare Funded Nursing Home Cuts Over Ten Years 55196 2Testosterone Therapy May Help Men With Heart Failure 55194 1Testosterone Therapy May Help Men With Heart Failure 55194 2Testosterone Therapy May Help Men With Heart Failure 55194 3